Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

77 - The role of Topoisomerase II-α (TOPO IIA) as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer

Date

05 Mar 2018

Session

Poster display

Presenters

Mohamed Gamea

Citation

Annals of Oncology (2018) 29 (suppl_3): iii10-iii34. 10.1093/annonc/mdy047

Authors

M.M. Gamea

Author affiliations

  • Clinical Oncology, gharbia cancer society, 31116 - tanta/EG
More

Resources

Abstract 77

Topoisomerase II-α is a molecular target of anthracyclines; several studies have suggested that topoisomerase II-α expression is related to response to anthracycline treatment. The objective of this study was to evaluate whether topoisomerase II-α overexpression predicts response to anthracycline treatment in locally advanced breast cancer patients.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings